Vaxxinity, Inc.
VAXX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VAXX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2023.
Tracking 5 pipeline candidates for Vaxxinity, Inc..
Run Vaxxinity, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vaxxinity, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
7.6 months
D/E 2.30
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$43
| Holder | Shares | Value |
|---|---|---|
| nbc securities, inc. | 1,592 | $43 |
Short Interest
as of Apr 29, 2026- % of float
- 108.7%
- Days to cover
- 14.0
- Shares short
- 4,220,918
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VAXX short interestGovernance
Frequently asked questions
What is Vaxxinity, Inc.'s lead drug candidate?
Vaxxinity, Inc.'s most advanced tracked candidate is ub-311 (Phase 2) for Alzheimer's Disease.
Who is the CEO of Vaxxinity, Inc.?
Ms. Mei Mei Hu J.D. is the chief executive officer of Vaxxinity, Inc. (VAXX).
Where is Vaxxinity, Inc. headquartered?
Vaxxinity, Inc. (VAXX) is headquartered in Merritt Island, FL, United States.
What therapeutic areas does Vaxxinity, Inc. focus on?
Vaxxinity, Inc. develops therapies across Neurology, Infectious Disease, Metabolic, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.